DR. RICHARD C BOUCHER, MD
Osteopathic Medicine at Manning Dr, Chapel Hill, NC
License number
North Carolina 22383
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
101 Manning Dr, Chapel Hill, NC 27599
Phone
(919) 966-4996
(919) 843-5515 (Fax)
(919) 843-5515 (Fax)
Organization information
See more information about RICHARD C BOUCHER at bizstanding.comRichard C Boucher
1124 Pinehurst Dr, Chapel Hill, NC 27517
Industry:
Commercial Physical Research
Controller:
Judy Mar (Controller)
Richard C Boucher MD
102 Mason Farm Rd #3, Chapel Hill, NC 27599
Categories:
Pulmonary & Respiratory Physicians & Surgeons
Phone:
(919) 966-6838 (Phone)
Unc Clinic - Richard C Boucher MD
101 Manning Dr #7001J, Chapel Hill, NC 27514
Categories:
Internal Medicine Physicians & Surgeons, Physicians & Surgeons, Pulmonary & Respiratory Physicians & Surgeons
Phone:
(919) 966-7890 (Phone)
Unc Pulmonary - Richard C Boucher MD
55 Cystic Fibrosis Ctr, Chapel Hill, NC 27599
Categories:
Physicians & Surgeons, Pulmonary & Respiratory Physicians & Surgeons
Phone:
(919) 966-7933 (Phone)
Professional information
Method Of Treating Lung Diseases With Uridine 5'-Diphosphate And Analogs Thereof
US Patent:
6022527, Feb 8, 2000
Filed:
Jul 13, 1999
Appl. No.:
9/352390
Inventors:
Richard C. Boucher - Chapel Hill NC
Sammy Ray Shaver - Chapel Hill NC
William Pendergast - Durham NC
Benjamin Yerxa - Raleigh NC
Janet L. Rideout - Raleigh NC
Robert Dougherty - Chapel Hill NC
Dallas Croom - Apex NC
Sammy Ray Shaver - Chapel Hill NC
William Pendergast - Durham NC
Benjamin Yerxa - Raleigh NC
Janet L. Rideout - Raleigh NC
Robert Dougherty - Chapel Hill NC
Dallas Croom - Apex NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
Inspire Pharmaceuticals, Inc. - Durham NC
Inspire Pharmaceuticals, Inc. - Durham NC
International Classification:
A61K 912
US Classification:
424 45
Abstract:
Compounds of Formula I: ##STR1## wherein: X. sub. 1, and X. sub. 2 are each independently either O. sup. - or S. sup. - ;
X. sub. 3 and X. sub. 4 are each independently either --H or --OH, with the proviso that X. sub. 3 and X. sub. 4 are not simultaneously --H;
R. sub. 1 is selected from the group consisting of O, imido, methylene and dihalomethylene;
R. sub. 2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxyl, nitro and azido;
R. sub. 3 is selected from the group consisting of H, alkyl, acyl, aryl, and arylalkyl; and
R. sub. 4 is selected from the group consisting of --OR', --SR', --NR', and --NR'R", wherein R' and R" are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R' is absent when R. sub. 4 is double bonded from an oxygen or sulfur atom to the carbon at the 4-position of the pyrimidine ring, are used in methods of hydrating lung mucus secretions and treating lung disorders such as cystic fibrosis, ventilator-associated pneumonia, chronic bronchitis, chronic obstructive pulmonary disorder and primary ciliary dyskinesia. Pharmaceutical compositions containing compounds of Formula I, and novel compounds of Formula I are also described.
Method Of Treating Retained Asthma Pulmonary Secretions
US Patent:
5849706, Dec 15, 1998
Filed:
Jan 28, 1998
Appl. No.:
/014757
Inventors:
Luis Miguel Molina y Vedia - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
David C. Henke - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
David C. Henke - Chapel Hill NC
Assignee:
Molichem Medicines, Inc. - Chapel Hill NC
The University of North Carolina at Chapel Hill - Chapel Hill NC
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 3800
US Classification:
514 12
Abstract:
A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.
Dinucleotides Useful For The Treatment Of Lung Disease
US Patent:
2001004, Nov 15, 2001
Filed:
May 7, 2001
Appl. No.:
09/850609
Inventors:
Monroe Stutts - Chapel Hill NC, US
Richard Boucher - Chapel Hill NC, US
Eduardo Lazarowski - Durham NC, US
Cara Geary - Seattle WA, US
Richard Boucher - Chapel Hill NC, US
Eduardo Lazarowski - Durham NC, US
Cara Geary - Seattle WA, US
International Classification:
A61K031/7076, A61K031/7068
US Classification:
514/047000, 514/051000
Abstract:
A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I):
wherein n is from 1 to 6; X is —OH or —SH; A and B are each independently selected from the group consisting of:
wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.
Dinucleotides Useful For The Treatment Of Lung Disease
US Patent:
6235266, May 22, 2001
Filed:
Apr 30, 1999
Appl. No.:
9/303491
Inventors:
Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durham NC
Cara A. Geary - Seattle WA
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durham NC
Cara A. Geary - Seattle WA
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 912
US Classification:
424 45
Abstract:
A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): ##STR1##
wherein
n is from 1 to 6;
X is --OH or --SH;
A and B are each independently selected from the group consisting of: ##STR2##
wherein R is H or Br;
or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.
Compounds And Methods For The Treatment Of Airway Diseases And For The Delivery Of Airway Drugs
US Patent:
2006014, Jun 29, 2006
Filed:
Feb 15, 2006
Appl. No.:
11/354740
Inventors:
Richard Boucher - Chapel Hill NC, US
International Classification:
A61K 31/70, A61K 31/28, A61K 31/285, A61K 31/205, A61K 31/198
US Classification:
514023000, 514492000, 514554000, 514561000, 514564000, 514565000, 514504000
Abstract:
Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
Method Of Treating Acid-Sensing Ion Channel Mediated Pain, Cough Suppression, And Central Nervous System Disorders
US Patent:
2008029, Nov 27, 2008
Filed:
Apr 3, 2008
Appl. No.:
12/061837
Inventors:
Michael R. JOHNSON - Chapel Hill NC, US
Richard C. BOUCHER - Chapel Hill NC, US
Andrew J. HIRSH - Durham NC, US
Richard C. BOUCHER - Chapel Hill NC, US
Andrew J. HIRSH - Durham NC, US
Assignee:
PARION SCIENCES, Inc. - Durham NC
International Classification:
A61K 31/4965, A61P 25/00
US Classification:
51425506
Abstract:
The present invention provides a variety of methods of treatment of acid-sensing ion channel (ASIC) mediated pain, cough, and central nervous system disorders by ASICs inhibition with a series of pyrazinoylguanidine compounds represented by formula (I) as defined herein.
Dinucleotides Useful For Hydrating Lung Mucous Secretions
US Patent:
5935555, Aug 10, 1999
Filed:
May 8, 1997
Appl. No.:
8/853056
Inventors:
Monroe Jackson Stutts - Chapel Hill NC
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durhm NC
Cara A. Geary - Seattle WA
Richard C. Boucher - Chapel Hill NC
Eduardo R. Lazarowski - Durhm NC
Cara A. Geary - Seattle WA
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 912
US Classification:
424 45
Abstract:
A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): ##STR1## wherein n is from 1 to 6;
X is --OH or --SH;
A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.
Methods Of Hydrating Lung Mucous Secretions With Benzamil Or Phenamil
US Patent:
5876700, Mar 2, 1999
Filed:
Jan 31, 1997
Appl. No.:
8/792887
Inventors:
Richard C. Boucher - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC
Monroe Jackson Stutts - Chapel Hill NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 912
US Classification:
424 45
Abstract:
Methods of hydrating lung mucous secretions in the lungs of a subject are disclosed. The methods involve administering benzamil or phenamil to the lungs of the subject in an amount effective to hydrate lung mucous secretions. The administering step is preferably carried out by inhalation administration. The method is useful in the treatment of diseases such as cystic fibrosis and chronic bronchitis.
Compounds And Methods For The Treatment Of Airway Diseases And For The Delivery Of Airway Drugs
US Patent:
2002009, Jul 25, 2002
Filed:
Mar 1, 2002
Appl. No.:
10/087355
Inventors:
Richard Boucher - Chapel Hill NC, US
International Classification:
A61K031/70, A61K031/198, A61K031/19, A61K031/14, A61K033/14, A01N033/12
US Classification:
514/023000, 424/646000, 424/663000, 424/664000, 514/557000, 514/564000, 514/642000
Abstract:
Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
Method Of Administering Amiloride
US Patent:
5725842, Mar 10, 1998
Filed:
Jan 5, 1996
Appl. No.:
8/583671
Inventors:
Richard C. Boucher - Chapel Hill NC
Michael R. Knowles - Chapel Hill NC
Michael R. Knowles - Chapel Hill NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 912
US Classification:
424 45
Abstract:
Methods are disclosed for removing retained mucus secretions from the lungs of a human subject. The method includes (1) generating an aerosol suspension of respirable solid, dry particulate amiloride, and (2) delivering by inhalation the aerosol suspension to the respiratory system of the subject. The solid particulate amiloride is comprised of particles of about 1 to 5 microns and is free of liquid amiloride particles. The aerosol suspension of respirable solid particulate amiloride is administered in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of from about 10. sup. -7 to 10. sup. -3 Moles/liter. As a result of the treatment, the secretions are hydrated and more easily transported from the lung via mucociliary action. Methods are also disclosed for the treatment of cystic fibrosis in humans.